How NAA10 and NAA15 Mutations Disrupt the Heart and What They Reveal About Cardiac Aging
Rare mutations in the NatA protein complex cause fatal heart defects — and the mechanisms may explain how normal cardiac aging goes wrong.
Summary
N-terminal acetylation is a fundamental process that chemically tags roughly 40% of all human proteins as they are built. The NatA complex — formed by two subunits called NAA10 and NAA15 — carries out most of this tagging. When either subunit is mutated, the result is a syndrome marked by developmental delay, skeletal problems, and, most critically, dangerous heart arrhythmias and structural cardiac defects that are the leading cause of death in affected patients. This review systematically maps how different mutation types undermine the NatA complex through four distinct routes: faulty complex assembly, impaired enzyme activity, protein instability, and disrupted ion channel regulation. The authors draw on data from patient-derived stem-cell heart models and biochemical studies. Crucially, they argue that insights from these rare syndromes — especially regarding proteostasis failure and ion channel dysfunction — shed new light on how the aging heart deteriorates more broadly.
Detailed Summary
N-terminal acetylation (NTA) is one of the most common protein modifications in eukaryotes, occurring co-translationally on roughly 40% of mammalian proteins. The NatA complex — comprising the catalytic subunit NAA10 and the auxiliary subunit NAA15 — is responsible for the majority of this modification. When pathogenic mutations strike either subunit, the consequences extend far beyond a biochemical curiosity: affected individuals develop serious multi-system syndromes, and it is cardiac dysfunction — life-threatening arrhythmias and structural abnormalities — that emerges as the predominant driver of mortality.
This review from China Medical University systematically dissects the mechanistic landscape of NAA10- and NAA15-related cardiac disease. The authors categorize how mutations derail cardiac function through four distinct pathways: disruption of NatA complex assembly, catalytic dysfunction (including impaired acetyltransferase activity and defective ribosome binding), protein destabilization, and ion channel dysregulation. Each pathway is linked to specific clinical phenotypes, creating a comprehensive genotype-phenotype map.
A key methodological strength of the evidence base discussed is the use of patient-derived induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) models, which allow researchers to interrogate the cellular consequences of individual mutations in a human cardiac context. These models, combined with biochemical studies, provide mechanistic resolution that animal models alone cannot.
Beyond the rare disease context, the authors make a compelling broader argument: the proteostasis failure and ion channel dysfunction seen in NatA-related syndromes mirror processes implicated in normal cardiac aging. As the heart ages, the proteostasis network declines and ion channel function becomes dysregulated — the same two axes disrupted in these genetic syndromes. Understanding the molecular mechanisms in the severe early-onset setting may therefore accelerate understanding of age-related cardiac decline.
Caveats include the rarity of the conditions, the reliance on limited patient cohorts, and the fact that this summary is based on the abstract only.
Key Findings
- Mutations in NAA10 or NAA15 impair NatA complex function across four mechanisms: faulty assembly, enzyme dysfunction, protein instability, and ion channel disruption.
- Cardiac arrhythmias and structural defects are the leading cause of death in NAA10- and NAA15-related syndromes.
- Patient-derived iPSC-cardiomyocyte models link specific mutations to precise cardiac cellular defects.
- Proteostasis failure and ion channel dysregulation in these syndromes parallel mechanisms of normal cardiac aging.
- Insights from these rare genetic disorders may inform therapeutic strategies for age-related heart disease.
Methodology
This is a systematic narrative review published in Ageing Research Reviews, integrating clinical phenotype data, patient-derived iPSC-cardiomyocyte studies, and biochemical analyses of NatA complex mutations. Evidence spans genotype-phenotype correlations, in vitro enzymatic assays, and cellular cardiac models. The review also critically evaluates current methodological gaps in the field.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting depth of assessment. The underlying conditions are rare, restricting the size of patient cohorts available for analysis. Translating mechanistic insights from severe early-onset genetic syndromes to common age-related cardiac disease requires further validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: